Application of a novel self-assembling peptide to prevent hemorrhage after EMR, a feasibility and safety study
| العنوان: | Application of a novel self-assembling peptide to prevent hemorrhage after EMR, a feasibility and safety study |
|---|---|
| المؤلفون: | Ayla S. Turan, Peter D. Siersema, Erwin J M van Geenen, Elsa Soons |
| المصدر: | Surgical Endoscopy Surgical Endoscopy and Other Interventional Techniques, 35, 3564-3571 Surgical Endoscopy and Other Interventional Techniques, 35, 7, pp. 3564-3571 |
| بيانات النشر: | Springer US, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, genetic structures, Endoscopic Mucosal Resection, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], Endoscopic mucosal resection, Hemorrhage, Topical agent, Article, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Prospective Studies, Esophagus, Prospective cohort study, Adverse effect, business.industry, Prophylaxis, Feasibility, Exploratory analysis, Hepatology, Surgery, medicine.anatomical_structure, Treatment Outcome, 030220 oncology & carcinogenesis, Duodenum, Delayed bleeding, Feasibility Studies, 030211 gastroenterology & hepatology, Safety, business, Peptides, Abdominal surgery |
| الوصف: | Background A novel self-assembling peptide (SAP) can be applied to the post-endoscopic mucosal resection (EMR) defect to treat oozing bleedings. It has been suggested to stimulate early healing of damaged vessels. We hypothesized that SAP application could prevent delayed bleeding (DB) after EMR and performed a prospective cohort study to determine feasibility and safety. Methods A total of 48 consecutive patients who underwent EMR between June 2018 and August 2019 for large lesions in the esophagus, duodenum (> 1 cm) or colorectum (> 2 cm) were treated with adjuvant SAP application. Duration and ease of SAP application were measured, as well as DB outcome. Results The EMR defects of 48 patients were treated with SAP; 17 in the esophagus, 13 in the duodenum and 18 in the colorectum. SAP was easy to apply on the EMR defect with a median duration of 2.0 min. A dose of 3 cc was generally enough to cover a defect between 10 and 50 mm. An exploratory analysis of the prophylactic ability of SAP showed that 15.9% of patients (7/44) treated with SAP still had a DB, mostly in the duodenum (4/11). No adverse events related to gel exposure were reported. Conclusions SAP application after EMR was found to be feasible and safe, and did not delay the procedure; however, DB was still relatively common. Future comparative studies are needed to evaluate whether SAP is able to reduce DB after EMR, particularly for lesions with an increased bleeding risk, such as in the duodenum. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1432-2218 0930-2794 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32d934a90f58f4c20315ad3bbc4b1d13Test http://europepmc.org/articles/PMC8195920Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....32d934a90f58f4c20315ad3bbc4b1d13 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14322218 09302794 |
|---|